Viewpoint: Glucocorticoids in the treatment of rheumatoid arthritis: points to (re)consider.

Authors:
Boers M.

Journal:
Rheumatology (Oxford)

Publication Year: 2023

DOI:
10.1093/rheumatology/kead309

PMCID:
PMC10629782

PMID:
37338537

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Rheumatology (Oxford)

Abbreviation: Rheumatology (Oxford)

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Accelerated atherosclerosis in systemic lupus erythematosus: don't forget the devil we know!
van Leuven SI; Major AS. (2024) - Transparency Score: 3/6
Addressing the unmet needs of transitional care in juvenile idiopathic arthritis.
Şahin N; Sönmez HE; Aktay Ayaz N and 1 more (2024) - Transparency Score: 3/6
Adherence to dietary guidelines, and the risk of developing rheumatoid arthritis: results from a ne…
Bäcklund RT; Drake I; Bergström U and 3 more (2024) - Transparency Score: 3/6
A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI'PsA).
Lioté F; Constantin A; Dahan É and 3 more (2024) - Transparency Score: 4/6
Autoimmune diseases exhibit shared alterations in the gut microbiota.
Wang T; Sternes PR; Guo XK and 3 more (2024) - Transparency Score: 5/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure statement: The author has received speaker fees from Novartis and Pfizer, provides expert testimony for Celltrion and was the principal investigator of two trials on glucocorticoids: COBRA and GLORIA."

Evidence found in paper:

"Funding No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article. Disclosure statement: The author has received speaker fees from Novartis and Pfizer, provides expert testimony for Celltrion and was the principal investigator of two trials on glucocorticoids: COBRA and GLORIA."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025